Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra®" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study
Jul 19, 2011
Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra®" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study
Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra®" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study